Tara M Connelly1, Walter A Koltun1, William Sangster1, Arthur S Berg2, John P Hegarty1, Leonard Harris1, Susan Deiling1, David B Stewart3. 1. Department of Surgery, Division of Colon & Rectal Surgery, The Pennsylvania State University, Hershey, PA. 2. Department of Public Health Sciences, The Pennsylvania State University, Hershey, PA. 3. Department of Surgery, Division of Colon & Rectal Surgery, The Pennsylvania State University, Hershey, PA. Electronic address: dstewart@hmc.psu.edu.
Abstract
BACKGROUND: Clinical studies have suggested that patients with inflammatory bowel disease (IBD) are at greater risk for developing Clostridium difficile infection (CDI). The purpose of this study was to identify single-nucleotide polymorphisms (SNPs) associated with CDI among IBD patients. METHODS: This retrospective cohort study used our biobank to compare patients with IBD who developed CDI (IBD-CDI) with those who had never contracted CDI (IBD-nCDI). Patients were genotyped for 384 IBD-associated SNPs by microarray. Student t, chi-square, and Fisher exact tests were used. Multivariate logistic regression with Bonferroni correction was used for genotype analysis. RESULTS: Twenty IBD-CDI (14 with Crohn disease; 6 with ulcerative colitis) and 152 IBD-nCDI (47 CD/105 UC) patients were identified. The interleukin-4-associated SNP rs2243250 was associated with the development of CDI (raw P = .00005/corrected P = .02), with 15 of 20 (75%) CDI-IBD patients harboring the at-risk "A" allele versus 52 of 152 (34%) of IBD-nCDI. When we compared Crohn disease and ulcerative colitis patients separately, rs2243250 initially was associated with CDI in both groups, although clinical relevance was lost after Bonferroni correction. CONCLUSION: The interleukin-4 gene-associated SNP rs2243250 was strongly associated with CDI in our IBD population. This SNP may allow for the identification of IBD patients at greater risk for CDI.
BACKGROUND: Clinical studies have suggested that patients with inflammatory bowel disease (IBD) are at greater risk for developing Clostridium difficileinfection (CDI). The purpose of this study was to identify single-nucleotide polymorphisms (SNPs) associated with CDI among IBD patients. METHODS: This retrospective cohort study used our biobank to compare patients with IBD who developed CDI (IBD-CDI) with those who had never contracted CDI (IBD-nCDI). Patients were genotyped for 384 IBD-associated SNPs by microarray. Student t, chi-square, and Fisher exact tests were used. Multivariate logistic regression with Bonferroni correction was used for genotype analysis. RESULTS: Twenty IBD-CDI (14 with Crohn disease; 6 with ulcerative colitis) and 152 IBD-nCDI (47 CD/105 UC) patients were identified. The interleukin-4-associated SNP rs2243250 was associated with the development of CDI (raw P = .00005/corrected P = .02), with 15 of 20 (75%) CDI-IBD patients harboring the at-risk "A" allele versus 52 of 152 (34%) of IBD-nCDI. When we compared Crohn disease and ulcerative colitispatients separately, rs2243250 initially was associated with CDI in both groups, although clinical relevance was lost after Bonferroni correction. CONCLUSION: The interleukin-4 gene-associated SNP rs2243250 was strongly associated with CDI in our IBD population. This SNP may allow for the identification of IBD patients at greater risk for CDI.
Authors: Julajak Limsrivilai; Krishna Rao; Ryan W Stidham; Shail M Govani; Akbar K Waljee; Andrew Reinink; Laura Johnson; Emily Briggs; Peter D R Higgins Journal: Dig Dis Sci Date: 2018-04-12 Impact factor: 3.199
Authors: Jiang Li; Yanfei Zhang; Alexandria L Jilg; Donna M Wolk; Harshit S Khara; Amy Kolinovsky; David D K Rolston; Raquel Hontecillas; Josep Bassaganya-Riera; Marc S Williams; Vida Abedi; Ming Ta Michael Lee Journal: Front Immunol Date: 2021-03-25 Impact factor: 7.561
Authors: Michael G Dieterle; Rosemary Putler; D Alexander Perry; Anitha Menon; Lisa Abernathy-Close; Naomi S Perlman; Aline Penkevich; Alex Standke; Micah Keidan; Kimberly C Vendrov; Ingrid L Bergin; Vincent B Young; Krishna Rao Journal: mBio Date: 2020-05-05 Impact factor: 7.867